| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Report from the FDA |
Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852
ABSTRACT
Purpose: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). In this study, we review the preclinical and clinical profiles of this immunoconjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration.
Experimental Design: From the literature and manufacturer’s data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclinical and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML.
Results: In Phase I studies, the major toxicity was myelosuppression, especially neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells. The Phase 2 dose was 9 mg/m2 infused i.v. over 4 h, repeated on day 14. A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization. The complete response (CR) rate with full recovery of hematopoiesis was 16%. A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery. The duration of responses of CRps appeared to be similar to those of the CRs, although the numbers were small. The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA). After considerable discussion, the Oncology Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%. In the subgroup of patients over 60 years of age, the overall response rate was 26%. Response duration was difficult to establish because of the high prevalence of postremission therapies. Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes. One patient died of liver failure in the Phase 2 trials.
Conclusions: Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations. Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. The approved dose was 9 mg/m2 i.v. over 4 h and repeated in 14 days. Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clinical trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clinical benefit under the accelerated approval Subpart H regulations. Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, especially venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without associated hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program. Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/ml treated with gemtuzumab ozogamicin; therefore, the reduction of leukocyte counts to below 30,000/ml is recommended prior to treatment. Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.
This article has been cited by other articles:
|
|
 |
|
  C. F. McDonagh, K. M. Kim, E. Turcott, L. L. Brown, L. Westendorf, T. Feist, D. Sussman, I. Stone, M. Anderson, J. Miyamoto, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther., September 1, 2008; 7(9): 2913 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Stahnke, T. Thepen, M. Stocker, R. Rosinke, E. Jost, R. Fischer, M. K. Tur, and S. Barth Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes Mol. Cancer Ther., September 1, 2008; 7(9): 2924 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bornhauser, T. Illmer, U. Oelschlaegel, J. Schetelig, R. Ordemann, M. Schaich, M. Hanel, U. Schuler, C. Thiede, A. Kiani, et al. Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia Clin. Cancer Res., September 1, 2008; 14(17): 5585 - 5593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Maniecki, H. Hasle, L. Friis-Hansen, B. Lausen, O. J. Nielsen, K. Bendix, S. K. Moestrup, and H. J. Moller Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin Blood, August 15, 2008; 112(4): 1510 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Kim, C. F. McDonagh, L. Westendorf, L. L. Brown, D. Sussman, T. Feist, R. Lyon, S. C. Alley, N. M. Okeley, X. Zhang, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity Mol. Cancer Ther., August 1, 2008; 7(8): 2486 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chakravarty, R. Marches, N. S. Zimmerman, A. D.-E. Swafford, P. Bajaj, I. H. Musselman, P. Pantano, R. K. Draper, and E. S. Vitetta Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes PNAS, June 24, 2008; 105(25): 8697 - 8702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fianchi, L. Pagano, F. Leoni, S. Storti, M. T. Voso, C. G. Valentini, S. Rutella, A. Scardocci, M. Caira, G. Gianfaldoni, et al. Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia Ann. Onc., January 1, 2008; 19(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hanbali, I. Wollner, K. Neme, and C. Ulreich Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1401 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Kennedy, T. K. Bera, Q.-C. Wang, M. Gallo, W. Wagner, M. G. Lewis, E. A. Berger, and I. Pastan Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques J. Leukoc. Biol., November 1, 2006; 80(5): 1175 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. McDonagh, E. Turcott, L. Westendorf, J. B. Webster, S. C. Alley, K. Kim, J. Andreyka, I. Stone, K. J. Hamblett, J. A. Francisco, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel., July 1, 2006; 19(7): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, R. J. Lutz, V. S. Goldmacher, and W. A. Blattler Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., April 15, 2006; 66(8): 4426 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ma, C. E. Hopf, A. D. Malewicz, G. P. Donovan, P. D. Senter, W. F. Goeckeler, P. J. Maddon, and W. C. Olson Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen Clin. Cancer Res., April 15, 2006; 12(8): 2591 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. V. Kovtun, C. A. Audette, Y. Ye, H. Xie, M. F. Ruberti, S. J. Phinney, B. A. Leece, T. Chittenden, W. A. Blattler, and V. S. Goldmacher Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res., March 15, 2006; 66(6): 3214 - 3221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Roman, E. Cooney, L. Harrison, O. Militano, K. Wolownik, R. Hawks, S. Foley, P. Satwani, E. Unal, M. Bhatia, et al. Preliminary Results of the Safety of Immunotherapy with Gemtuzumab Ozogamicin following Reduced Intensity Allogeneic Stem Cell Transplant in Children with CD33+ Acute Myeloid Leukemia Clin. Cancer Res., October 1, 2005; 11(19): 7164s - 7170s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Arceci, J. Sande, B. Lange, K. Shannon, J. Franklin, R. Hutchinson, T. A. Vik, D. Flowers, R. Aplenc, M. S. Berger, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia Blood, August 15, 2005; 106(4): 1183 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P Levene, G. Singh, and C. Palmieri Therapeutic monoclonal antibodies in oncology J R Soc Med, April 1, 2005; 98(4): 146 - 152. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Sanderson, M. A. Hering, S. F. James, M. M.C. Sun, S. O. Doronina, A. W. Siadak, P. D. Senter, and A. F. Wahl In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate Clin. Cancer Res., January 15, 2005; 11(2): 843 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma Clin. Cancer Res., December 15, 2004; 10(24): 8620 - 8629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tassone, V. S. Goldmacher, P. Neri, A. Gozzini, M. A. Shammas, K. R. Whiteman, L. L. Hylander-Gans, D. R. Carrasco, T. Hideshima, R. Shringarpure, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells Blood, December 1, 2004; 104(12): 3688 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nabhan, L. Rundhaugen, M. Jatoi, M. B. Riley, L. Boehlke, L. C. Peterson, and M. S. Tallman Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease Ann. Onc., August 1, 2004; 15(8): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buckwalter, J. A. Dowell, J. Korth-Bradley, B. Gorovits, and P. R. Mayer Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia J. Clin. Pharmacol., August 1, 2004; 44(8): 873 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al. In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells Cancer Res., July 1, 2004; 64(13): 4629 - 4636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Crombet, M. Osorio, T. Cruz, C. Roca, R. del Castillo, R. Mon, N. Iznaga-Escobar, R. Figueredo, J. Koropatnick, E. Renginfo, et al. Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients J. Clin. Oncol., May 1, 2004; 22(9): 1646 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qi, T. M. Nett, M. C. Allen, X. Sha, G. S. Harrison, B. A. Frederick, E. D. Crawford, and L. M. Glode Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor Cancer Res., March 15, 2004; 64(6): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. DiJoseph, D. C. Armellino, E. R. Boghaert, K. Khandke, M. M. Dougher, L. Sridharan, A. Kunz, P. R. Hamann, B. Gorovits, C. Udata, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies Blood, March 1, 2004; 103(5): 1807 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Tur, M. Huhn, T. Thepen, M. Stocker, R. Krohn, S. Vogel, E. Jost, R. Osieka, J. G. van de Winkel, R. Fischer, et al. Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells Cancer Res., December 1, 2003; 63(23): 8414 - 8419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J Giles, J. E Cortes, T. A Halliburton, S. J Mallard, E. H Estey, T. A Waddelow, and J. T Lim Intravenous Corticosteroids to Reduce Gemtuzumab Ozogamicin Infusion Reactions Ann. Pharmacother., September 1, 2003; 37(9): 1182 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wadleigh, P. G. Richardson, D. Zahrieh, S. J. Lee, C. Cutler, V. Ho, E. P. Alyea, J. H. Antin, R. M. Stone, R. J. Soiffer, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood, September 1, 2003; 102(5): 1578 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mitchell, F.-T. Lee, C. Hall, A. Rigopoulos, F. E. Smyth, A.-M. Hekman, G. M. van Schijndel, R. Powles, M. W. Brechbiel, and A. M. Scott Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies J. Nucl. Med., July 1, 2003; 44(7): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Zwaan, D. Reinhardt, S. Corbacioglu, E. R. van Wering, J. P. M. Bokkerink, W. J. E. Tissing, U. Samuelsson, J. Feingold, U. Creutzig, and G. J. L. Kaspers Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis Blood, May 15, 2003; 101(10): 3868 - 3871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawakami, M. Kawakami, S. R. Husain, and R. K. Puri Effect of Interleukin (IL)-4 Cytotoxin on Breast Tumor Growth after in Vivo Gene Transfer of IL-4 Receptor {alpha} Chain Clin. Cancer Res., May 1, 2003; 9(5): 1826 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone The Difficult Problem of Acute Myeloid Leukemia in the Older Adult CA Cancer J Clin, November 1, 2002; 52(6): 363 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
